Shanghai Haohai Biological Technology Co (FRA:5HB) Ending Cash Position: €87.6 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:5HB Shanghai Haohai Biological Technology Co Ltd FRA:5HB
86 GF Score
Price €1.75
GF Value €2.75
! 5 Warning Signs
View Full Analysis

What is Shanghai Haohai Biological Technology Co Ending Cash Position?

Shanghai Haohai Biological Technology Co FRA:5HB 86 Ending Cash Position is €87.6 Mil as of Mar. 2026. GuruFocus rates FRA:5HB with a GF Score™ of 86/100 and a GF Value™ of €2.75. The stock has 5 warning signs investors should review.

Shanghai Haohai Biological Technology Co's Ending Cash Position for the quarter that ended in Mar. 2026 was €87.6 Mil.

Shanghai Haohai Biological Technology Co's quarterly Ending Cash Position increased from Sep. 2025 (€18.1 Mil) to Dec. 2025 (€56.1 Mil) and increased from Dec. 2025 (€56.1 Mil) to Mar. 2026 (€87.6 Mil).

Shanghai Haohai Biological Technology Co's annual Ending Cash Position increased from Dec. 2023 (€73.1 Mil) to Dec. 2024 (€146.0 Mil) and increased from Dec. 2024 (€146.0 Mil) to Dec. 2025 (€148.9 Mil).

Shanghai Haohai Biological Technology Co Ending Cash Position Related Terms

Shanghai Haohai Biological Technology Co Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Shanghai Haohai Biological Technology Co's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shanghai Haohai Biological Technology Co Ending Cash Position Chart

Shanghai Haohai Biological Technology Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 178.39 75.72 73.12 145.98 148.95

Shanghai Haohai Biological Technology Co Quarterly Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Jun25 Sep25 Dec25 Mar26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 25.64 0.00 18.14 56.08 87.64
FRA:5HB
86GF Score
Shanghai Haohai Biological Technology Co Ltd FRA:5HB
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Shanghai Haohai Biological Technology Co Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Shanghai Haohai Biological Technology Co's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=134.941+14.004
=148.9

Shanghai Haohai Biological Technology Co's Ending Cash Position for the quarter that ended in Mar. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=154.172+-66.535
=87.6

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of €87.6 Mil mean?
Shanghai Haohai Biological Technology Co (FRA:5HB) has a Ending Cash Position of €87.6 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Shanghai Haohai Biological Technology Co and its competitors.
Is Shanghai Haohai Biological Technology Co's Ending Cash Position too high?
Shanghai Haohai Biological Technology Co's current Ending Cash Position is €87.6 Mil. Overall, Shanghai Haohai Biological Technology Co has a GF Score™ of 86/100, reflecting its overall financial health beyond just this single metric.
How does Shanghai Haohai Biological Technology Co's Ending Cash Position compare to VRTX and REGN?
Shanghai Haohai Biological Technology Co's Ending Cash Position of €87.6 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Shanghai Haohai Biological Technology Co and its competitors. Shanghai Haohai Biological Technology Co's current Ending Cash Position is €87.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Haohai Biological Technology Co stock overvalued right now?
Shanghai Haohai Biological Technology Co (FRA:5HB) has a current Ending Cash Position of €87.6 Mil. The stock's GF Value™ is €2.75, compared to a current price of €1.75 — trading 36.4% below its estimated fair value. The current Ending Cash Position is €87.6 Mil. Shanghai Haohai Biological Technology Co's overall GF Score™ is 86/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Shanghai Haohai Biological Technology Co (FRA:5HB), the current Ending Cash Position is €87.6 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Shanghai Haohai Biological Technology Co (FRA:5HB) Overvalued in 2026?

Based on GuruFocus' analysis, Shanghai Haohai Biological Technology Co stock appears to be undervalued. The current stock price of €1.75 is trading 36.4% below its estimated GF Value™ of €2.75.

Key valuation signals for FRA:5HB:

  • Ending Cash Position: €87.6 Mil
  • GF Value™: €2.75 vs. price of €1.75 (36.4% below fair value)
  • GF Score™: 86/100 with 5 warning signs

No single metric tells the full story. See the FRA:5HB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Shanghai Haohai Biological Technology Co Business Description

Other Exchanges 06826:Hong Kong688366:China
Address No. 1386 Hongqiao Road, 23rd Floor, WenGuang Plaza, Changning District, Shanghai, CHN
Shanghai Haohai Biological Technology Co Ltd is engaged in the manufacturing and sale of biologicals, medical hyaluronate, and ophthalmology products. The Company's operating activities are related to a single operating segment, which is the manufacture and sale of biologicals, medical hyaluronate, and intraocular lenses, research and development of biological engineering and pharmaceutical products, and the provision of related services. Its products are categorized into four types, comprising ophthalmology, medical aesthetics, orthopedics, and anti-adhesion. Geographically, it has operations in Mainland China, which is the key revenue driver, the United States, the United Kingdom, and other countries.
86GF Score

Get the complete analysis for FRA:5HB

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.75
Price
€2.75
GF Value